| Document |
Document Title |
|
WO/2020/242849A1 |
Provided are methods for clinical treatment of vitiligo using an anti-C5 antibody or antigen binding fragment thereof.
|
|
WO/2020/243228A1 |
Polyphosphate activates the intrinsic pathway of coagulation that also induces inflammation. Hypercoagulable and hyperinflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death, which occur in m...
|
|
WO/2020/238420A1 |
Disclosed are a drug for treating leukopenia, a preparation method therefor and the use thereof. The drug is prepared from the following raw materials in parts by weight: 200-300 parts of Epimedii folium, 100-160 parts of Psoraleae fruct...
|
|
WO/2020/243612A1 |
A method of preventing or treating thrombosis in a patent is disclose, wherein the method comprises administering to the patient an amount of fostamatinib or a form or metabolite thereof effective to prevent or treat the thrombosis, resp...
|
|
WO/2020/243049A1 |
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...
|
|
WO/2020/239135A1 |
The present invention relates to a high anticoagulation activity compound, a preparation method and an application, said compound being formed from a monosaccharide unit D, a monosaccharide unit E, a 6-position carbon oxygen-substituted ...
|
|
WO/2020/237307A1 |
Disclosed are anti-thrombotic agents. More particularly, chimeric molecules are disclosed, which target multiple pathways in the coagulation cascade and which comprise an anti-coagulant agent and an anti-platelet antigen-binding molecule...
|
|
WO/2020/239986A1 |
The invention relates to a pharmaceutical composition in the form of a tablet, comprising a) edoxaban, or a salt thereof or a hydrate of said edoxaban or edoxaban salt, as an active ingredient, b) lactose as a water-soluble filler, and c...
|
|
WO/2020/233288A1 |
The present invention relates to the technical field of biomedicine, and relates in particular to a torsemide sodium monohydrate, a crystal form thereof and a composition thereof. The beneficial effects of the present invention are that ...
|
|
WO/2020/233226A1 |
Disclosed in the present invention are a B crystal form of a tetrahydrothienopyridine compound having a structure as represented by formula I, a preparation method therefor, a composition and an application, for use in solving the proble...
|
|
WO/2020/233650A1 |
Provided are an siRNA which inhibits plasma coagulation factor XI gene expression, a pharmaceutical composition containing the siRNA, a conjugate, a reagent kit, and a use of the siRNA, the pharmaceutical composition thereof and the conj...
|
|
WO/2020/236612A1 |
The present invention relates to methods and compositions for treating a hematological malignancy with an expanded hematopoietic stem cell product in combination with a chemotherapy regimen.
|
|
WO/2020/233289A1 |
The present invention relates to the technical field of biological medicine, in particular to a torasemide phosphate prodrug, a preparation method therefor and a composition having same. The torasemide prodrug, N-hydroxymethyl-torasemide...
|
|
WO/2020/237047A1 |
Provided herein are various crystalline salt forms of compound (I) represented by the following structural formula: Also provided are pharmaceutical compositions comprising the crystalline salt forms, methods for their manufacture, and u...
|
|
WO/2020/233588A1 |
Disclosed are a new crystal form of a treprostinil sodium salt (the structural formula thereof is shown as formula I) and a preparation method therefor. Specifically, disclosed are a five and half hydrates of the treprostinil sodium salt...
|
|
WO/2020/229621A1 |
Immunoglobulin lambda variable domain sequence adapted for expression with non-native N terminal signal peptide, comprising a deletion at IMGT position 1.
|
|
WO/2020/229761A1 |
The invention relates to a pharmaceutical composition, comprising at least one compound of the echinocandin family and at least one other therapeutically active ingredient except for hypouricemic compounds, intended to be used as a cytop...
|
|
WO/2020/232263A1 |
Methods for treating obesity, atherosclerosis, and/or thrombosis comprise reducing an expression level or activity of thymidine phosphorylase in a subject in need thereof. Reducing the expression level or activity of thymidine phosphoryl...
|
|
WO/2020/227851A1 |
Disclosed is a composition for use in preparation of a dialysis solution, at least comprising a first substance and a second substance, wherein the first substance comprises or can generate phosphate, and the second substance comprises o...
|
|
WO/2020/227643A1 |
Provided herein are methods and related compositions and kits for dissolution of platelet clumps formed in collected blood samples. The present methods, compositions and kits are useful for improving blood sample quality and blood assay ...
|
|
WO/2020/226602A1 |
A combined haemostatic agent for stopping bleeding relates to medicine, in particular to surgery, and can be used for rapidly stopping profuse bleeding during surgical interventions, in the provision of first aid in the event of wounds a...
|
|
WO/2020/226526A1 |
The invention relates to the field of medicine, particularly to a method for increasing blood haemoglobin level in a cancer patient. A method for increasing blood haemoglobin level in a cancer patient, wherein a pharmaceutical composi...
|
|
WO/2020/227637A1 |
The present disclosure provides methods and compositions for generating populations of auxotrophic cells and populations of differentiated cells and selecting populations of transfected cells using split auxotrophy.
|
|
WO/2020/227162A1 |
Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs), e.g., Factor VIII (FVIII) including PEGylated and other forms of stabilized FVIII, within the GI tract. Many em...
|
|
WO/2020/227314A1 |
Disclosed herein are precursory regulatory cytotrophoblast cells produced in vitro and compositions thereof. Also disclosed herein are methods of treating a disorder or condition by utilizing the cells disclosed herein.
|
|
WO/2020/226907A1 |
The present invention relates to single domain antibodies (sdAbs) against TREM (triggering receptors expressed on myeloid cells) like transcript-1 (TLT-1) molecules that are present on activated platelets at the site of an injury, and es...
|
|
WO/2020/223436A1 |
Methods of inhibiting expansion of cerebral contusion, inhibiting secondary hemorrhage and capillary fragmentation in the brain, reducing pericontusional edema and hemorrhage size in the brain, decreasing water content in a CNS tissue, i...
|
|
WO/2020/221291A1 |
The present invention relates to a method for treating hemoglobinopathy in an individual, comprising: (a) an evaluation step: the evaluation step comprises evaluating the ability of a first population of modified CD34-positive hematopoie...
|
|
WO/2020/222302A1 |
The present invention relates to a pharmaceutical composition that is used for treating or preventing acidosis of chronic kidney disease with anemia and contains citric acid, a pharmaceutically acceptable salt of citric acid, a hydrate t...
|
|
WO/2020/221309A1 |
Provided is a small activating nucleic acid molecule which increases HMBS gene expression, and an application thereof. The small activating nucleic acid molecule is a double-stranded or single-stranded RNA molecule targeting the HMBS gen...
|
|
WO/2020/215999A1 |
Use of trifluridine or a trifluridine tipiracil composition in the preparation of a medicament for treating blood diseases. Specifically involved is use in the preparation of a medicament for treating blood diseases caused by a β-hemogl...
|
|
WO/2020/217567A1 |
The present invention provides a hydrogen gas dissolution method for dissolving hydrogen gas in a liquid contained in a flexible container capable of expanding and shrinking, the method including: causing a bottle needle to penetrate thr...
|
|
WO/2020/219384A1 |
The present disclosure provides an apixaban transdermal patch for treatment of thrombosis and related disorders. The transdermal patch may be administered on a daily basis or a period of 2 days, 3 days, 4 days, 5 days, 6 days or 7 days. ...
|
|
WO/2020/219964A1 |
The disclosure provides compositions and methods useful for the depletion of a specific population of endogenous hematopoietic stem cells and/or immune cells from a subject prior to transplantation with genetically modified stem cells to...
|
|
WO/2020/218829A1 |
The present invention relates to a flagellin fusion protein and a use thereof and, more specifically, to a fusion protein comprising: flagellin, a fragment thereof, or a variant thereof; and an immunoglobulin Fc region, and a use in whic...
|
|
WO/2020/215895A1 |
The present invention relates to the technical field of medicine, and relates to derivatives represented by formula 1 and formula 2 in which a carboxylic acid group is introduced into the structure of ginkgolide B by means of a hydroxyl ...
|
|
WO/2020/219557A1 |
The present disclosure provides compositions comprising a magnetic probe and a live or inert platelet cell or platelet mimicking system, and methods of using the same.
|
|
WO/2020/219845A1 |
The present disclosure provides improved genome editing compositions and methods for editing a human Wiskott-Aldrich syndrome gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at ...
|
|
WO/2020/214929A1 |
Provided herein are formulations comprising recombinant AAV particles. In some embodiments, the formulation is a frozen formulation or a lyophilized formulation. Also provided herein are methods for reducing rAAV genome release from rAAV...
|
|
WO/2020/211009A1 |
Disclosed is a therapeutic use of an extract from rabbit skin inflamed by vaccinia virus. Particularly, disclosed is a use of an extract from rabbit skin inflamed by vaccinia virus in treating hematopoietic system damage or pancytopenia ...
|
|
WO/2020/211751A1 |
The compound shown in formula I, and racemates, stereoisomers, tautomers, isotopic markers, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts, or prodrugs thereof. The compound shown in formula...
|
|
WO/2020/211674A1 |
The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing ...
|
|
WO/2020/213012A1 |
The present disclosure provides a composition comprising: a polyanionic component comprising casein or derivatives thereof; and a polycationic component comprising chitosan or derivatives thereof, wherein the composition is in the form o...
|
|
WO/2020/215091A1 |
Disclosed herein are compositions, methods, and systems useful in the prevention, management, or treatment of various conditions associated the lymphatic vasculature, including, but not limited to lymphedema. The disclosed methods and co...
|
|
WO/2020/210087A1 |
The present invention relates to rusalatide acetate compositions, formulations and dosage forms that include 23 amino acid monomer ("Monomer"), dimer ("Dimer") of two 23 amino acid Monomers, or any combination of Monomer and Dimer, where...
|
|
WO/2020/209285A1 |
Developed were: a nucleic acid complex that exhibits an excellent anti-sense effect in skeletal muscle and/or cardiac muscle; and a therapeutic or prophylactic composition that contains said nucleic acid complex as the active ingredient,...
|
|
WO/2020/210339A1 |
The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present invention is also related a method of controlling the activity or the amount, or both the activity and the amou...
|
|
WO/2020/207355A1 |
Provided is a pharmaceutical composition for treating refractory hypertension. The pharmaceutical composition consists of amlodipine, chlorthalidone, and amiloride. The provided pharmaceutical composition provides an effective antihypert...
|
|
WO/2020/209059A1 |
This disclosure provides a pharmaceutical composition for treating hyperammonemia that contains α-ketoglutaric acid or dimethyl-α-ketoglutaric acid, or a pharmaceutically acceptable salt thereof.
|
|
WO/2020/210629A1 |
This invention relates to solid amorphous Compound (I) having the formula (I) and to solid amorphous dispersions comprising Compound (I) and one or more polymers or to solution formulations comprising Compound (I) and one or more co-solv...
|
